OUR VISION
We are building a leading, next generation precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology
EXACT Therapeutics present full results from ACTIVATE trial at ESMO conference
Conclusions:
ACT treatment was safe and did not worsen side effects of chemotherapy,
ACT treatment is deliverable in out-patient settings
Treatment with ACT + CTx showed greater response compared with CTx alone,
The effect of ACT was significantly greater in subjects who had any response to chemotherapy*,
The ACTIVATE study provided proof of concept that treatment with ACT + CTx has the potential to be more efficacious than treatment with CTx alone,
The ACT technology is currently being evaluated in a Phase 2 study in locally advanced pancreatic cancer - ENACT study (NCT06850623).
KEY FOCUS AREA
Focus on Oncology
We are united in the mission:
ACT® against pancreatic cancer
Latest company news:
-
Poster presentationt at the European Society for Medical Oncology (ESMO) Congress 2025
Clinical data from the ACTIVATE Phase 1 trial in patients with liver metastases of colorectal origin was presented at the European Society for Medical Oncology (ESMO) Congress 2025
-
Phase 2 trial presented at the 2025 AACR Special Conference
Poster on the ongoing Phase 2 ENACT trial in locally advanced pancreatic cancer patients was presented at the 2025 AACR Special Conference on the Advances in Pancreatic Cancer Research
-
Core patent granted in the USA
On July 8, EXACT was granted a core patent that covers the treatment of patients with a pharmaceutical using EXACT’s proprietary agent PS101 and Acoustic Cluster Therapy (ACT®)
-
First patient dosed in Phase 2 trial
EXACT announces first patient dosed in its ENACT trial on June 24, 2025
Our pipeline
Our technology
The Key differentiation of ACT® is:
ACT® has a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding (cancer) tissue, without damaging the cells within the capillary walls; unlike sonoporation, ACT® does not create holes in the epithelial cell membranes of the capillary wall.
With ACT®, the drug can reach 100 microns which is 10 layers of cells away from capillary with an ongoing pump effect that lasts for minutes.
Reproducible and signifcant uptake through targeted delivery into tumours and across the blood brain barrier (BBB).
A very strong toxicology package:
including most recently, in relation to BBB opening where no extravasation of red blood cells was observed throughout the ACT® procedure in a preclinical rodent model.
Uses a bespoke dual frequency transducer with a standard ultrasound scanner to activate and enhance the clusters at the target tumour site. Compatible with existing ultrasound systems widely available in clinics/hospitals worldwide.
No drug reformulation required.
ACT® relies on ultrasound settings well within safe and approved ranges.
State of the art navigation system in development to ensure ACT® is delivered accurately at a targeted site